• Molecular NameTrazodone
  • SynonymTrazodona [INN-Spanish]; trazodone; Trazodone Hcl; Trazodone Hydrochloride; Trazodonum [INN-Latin]
  • Weight371.872
  • Drugbank_IDDB00656
  • ACS_NO19794-93-5
  • Show 3D model
  • LogP (experiment)3.8
  • LogP (predicted, AB/LogP v2.0)3.44
  • pkaN/A
  • LogD (pH=7, predicted)3.26
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.41
  • LogSw (predicted, AB/LogsW2.0)0.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.07
  • No.of HBond Donors0
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA42.39
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA psychoactive drug of the piperazine and triazolopyridine chemical classes that has antidepressant, anxiolytic, and hypnotic properties.
  • Absorption_value100.0
  • Absorption (description)Trazodone is well absorbed after oral administration with mean peak blood levels obtained at approximately 1 hour after ingestion. Absorption is somewhat delayed and enhanced by food.
  • Caco_2N/A
  • Bioavailability81.0
  • Protein binding93.0
  • Volume of distribution (VD)1.0 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmActive metabolite, m-chlorophenylpiperazine, is a tryptaminergic agonist; formation catalyzed by CYP3A.
  • Half life5.9 h
  • Excretion20% feces, 80% urine
  • Urinary Excretion<1
  • Clerance2.1 ml/min/kg
  • ToxicityLD50=96mg/kg (i.v. in mice)
  • LD50 (rat)N/A
  • LD50 (mouse)N/A